Navigation Links
Calcium plus vitamin D supplementation does not reduce joint symptoms in postmenopausal women
Date:8/16/2013

Philadelphia, PA, August 15, 2013 A team of investigators systematically analyzed the effect of calcium and vitamin D supplementation on joint symptoms in a rigorous and controlled study of postmenopausal women. They found that supplementation did not reduce the severity of joint symptoms reported by the participants. Their results are published in the Journal of the Academy of Nutrition and Dietetics.

The influence of low calcium and vitamin D deficiency on joint symptoms has been studied with mixed results. Only some observational studies have associated vitamin D with knee osteoarthritis and results from full-scale randomized trials have been sparse. "In the current study, we addressed for the first time in a full-scale, randomized clinical trial setting, the clinically relevant question of whether postmenopausal women using calcium and vitamin D supplements in currently recommended dosage would experience any favorable effect on joint pain or swelling, common symptoms in postmenopausal women," says lead investigator Rowan T. Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Torrance, California.

Using data from the Women's Health Initiative (WHI) calcium plus vitamin D supplementation trial, researchers identified a subgroup of 1,911 postmenopausal women for the current study, who had been randomized to receive calcium carbonate with vitamin D3 daily or placebo and had undergone serial joint symptom assessment. Responses to a questionnaire provided qualitative information on joint pain and joint swelling before entry and two years after randomization.

Between the daily supplement use and placebo groups, joint pain and swelling at baseline entry was comparable, at more than 70 percent. After two years, analysis revealed no statistically significant difference for the frequency or severity of joint pain or swelling.

The research team also evaluated data to determine the potential for interaction with age, BMI (body mass index), physical activity, non-protocol calcium and vitamin D supplement use, race/ethnicity, and hormone therapy. Investigators found no interaction with age, BMI, race/ethnicity, or physical activity. No significant interaction was evident with non-protocol vitamin D supplement use at entry. However, participants using non-protocol calcium supplements at entry reported less joint pain compared with those in the placebo group. The influence of calcium and vitamin D supplementation individually on joint symptoms was not determined because both were provided combined in a single pill in this trial.

Dr. Chlebowski concludes, "Joint symptoms are relatively common in postmenopausal women. However, daily supplementation with 1,000 mg of calcium carbonate and 400 IU of vitamin D3 in a randomized, placebo-controlled clinical trial setting did not reduce the self-reported frequency or severity of joint symptoms."

Dr. Chlebowski and his team add that these findings do not speak against current recommendations for vitamin D intakes for bone health and fracture risk reduction.


'/>"/>

Contact: Eileen Leahy
andjrnlmedia@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Heart study suggests city center pollution doubles risk of calcium build-up in arteries
2. Vitamin D with calcium shown to reduce mortality in elderly
3. Diets high in salt could deplete calcium in the body: UAlberta research
4. New research: Soluble corn fiber plays important role in gut health and calcium absorption
5. Danish researchers release ground-breaking knowledge about calcium pumps in cells
6. New health-economic model shows benefits of boosting dietary calcium intake
7. Calcium supplements remain a valuable tool for maintaining bone health
8. Temple-Penn researchers identify calcium accelerator to keep cell power supply going
9. Community-based nutrition education shown to be successful in increasing calcium intake
10. Hebrew University study finds key mechanism in calcium regulation
11. Waste removal in worms reveals new mechanism to regulate calcium signaling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/3/2016)... 3, 2016 ... the "Emotion Detection and Recognition Market ... Others), Software Tools (Facial Expression, Voice Recognition ... Regions - Global forecast to 2020" ... http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the addition ...
(Date:2/2/2016)... This BCC Research report provides a ... the recent advances in high throughput ‘omic platforms ... forward. Includes forecast through 2019. Use ... opportunities that exist in the bioinformatic market. Analyze ... well as IT and bioinformatics service providers. Analyze ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... ... ... Information Management Services ( IMS ) is pleased to announce a major upgrade ... and is so significant it was endowed with a new name, BSI Engage. ... a streamlined layout and a more intuitive format for navigating the system. ...
(Date:2/8/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, ... mobile-friendly. Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create ...
(Date:2/5/2016)...  In the pharmaceutical industry the medical affairs function ... activities including the identification and engagement of key thought ... high in the oncology therapeutic area where most treating ... Role of Medical Affairs in Oncology Launch Excellence ." ... find better ways to utilize medical affairs to develop ...
(Date:2/4/2016)... 4, 2016 - New FDA action date of ... New FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast ... decade indicated for the treatment of signs and symptoms of dry ... the potential to be the only product approved in the U.S. in the past decade ...
Breaking Biology Technology: